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Background: Canine degenerative myelopathy (CDM) is an adult onset, progressive neurodegenerative disease of
the spinal cord. The disease was originally described in the German Shepherd dog (GSD), but it is now known to
occur in many other dog breeds. A previous study has identified a mutation in the superoxide dismutase 1 gene
(SOD1:c.118G > A) that is associated with susceptibility to CDM. In the present study, restriction fragment length
polymorphism (RFLP) analysis was used to genotype GSD for SOD1:c.118G > A in order to estimate the prevalence
of the mutation in a referral population of GSD in the UK.
Results: This study demonstrated that the RFLP assay, based on use of PCR and subsequent digestion with the
Eco571 enzyme, provided a simple genotyping test for the SOD1:c.118G > A mutation. In a young GSD population
(i.e. dogs less than 6 years of age, before clinical signs of the disease usually become apparent), 8 of 50 dogs
were found to be homozygous and a further 19 were heterozygous for the mutation. In dogs over 8 years of
age, 21 of 50 dogs admitted to a tertiary referral hospital with pelvic limb ataxia as a major clinical sign were
homozygous for the mutation, compared to none of 50 dogs of similar age, but where no neurological disease was
reported on referral.
Conclusions: This data suggests that genotyping for the SOD1:c.118G > A mutation is clinically applicable and that the
mutation has a high degree of penetrance. Genotyping might also be useful for screening the GSD population to
avoid mating of two carriers, but since the allele frequency is relatively high in the UK population of GSD, care should
be taken to avoid reduction in genetic diversity within the breed.
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Canine degenerative myelopathy (CDM) is an adult onset,
progressive disease where the spinal nerve cord degenerates.
This disease occurs in several dog breeds, but German
shepherd dogs (GSD) are particularly susceptible. A pre-
vious study identified a genetic change (mutation) in the* Correspondence: aholder@rvc.ac.uk
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unless otherwise stated.superoxide dismutase 1 gene (SOD1) that is associated
with susceptibility to CDM.
Protein sequences in the body are made up of different
types of building blocks called amino acids. Each type of
amino acid is encoded by particular DNA code. The mu-
tation, called SOD1:c.118G>A, encodes a change in the
SOD1 protein (amino acid position 118 of the protein),
where the usual amino acid glycine (G) has been re-
placed by the amino acid alanine (A), thus changing the
structure and possible function of the protein.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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type assay (called restriction fragment length polymorph-
ism, RFLP) was used to genotype German shepherd dogs
for the SOD1 mutation to estimate how frequently it
occurs in this breed in the UK.
This study demonstrated that the genetic assay pro-
vided a simple test for the SOD1 mutation. In a young
GSD population (i.e. dogs less than six years of age, be-
fore clinical signs of the disease usually become appar-
ent), 8 of 50 dogs were found to carry two copies of the
mutation (homozygous), a further 19 carried one copy
(heterozygous for the mutation), while the remainder
had no copies, (homozygous normal). In GSD dogs over
eight years of age, 21 of 50 dogs admitted to a tertiary
referral hospital with clinical signs of neurodegeneration
(pelvic limb ataxia) were homozygous for the mutation,
and 29 were heterozygous. In contrast, none of 50 GSD
dogs of similar age, with no reported neurological dis-
ease were homozygous for the mutation, while 26 were
heterozygous.
This study suggests that genotyping for the SOD1 mu-
tation may be clinically useful. Genotyping might also be
used for screening the GSD population to avoid mating
of two carriers. However, because the frequency of the
mutation is relatively high in the UK population of GSD,
extreme care should be taken to avoid reduction in gen-
etic diversity within the breed.
Background
Canine degenerative myelopathy (CDM) is a progressive
neurodegenerative disease of the spinal cord. The disease
was originally described in the German Shepherd dog
(GSD) [1], where it is a main cause of premature mortal-
ity [2], but it has since been shown to occur in many
other dog breeds [3]. The onset of clinical signs typically
occurs from around 8 years of age, with dogs showing
asymmetric progressive upper motor neuron paraparesis
and ataxia of the pelvic limbs, worn nails and a lack of
spinal pain upon palpation of the vertebral column.
Paraparesis progresses to lower motor neuron paraplegia
within 9 to 18 months, usually necessitating euthanasia
[3]. However, if euthanasia is delayed, as is possible in
smaller breeds where care at home can be given for lon-
ger, clinical signs can progress to the thoracic limbs [4].
Post-mortem histology is most compatible with a pri-
mary central axonopathy of the spinal cord. Axons and
associated myelin degenerate in a segmental pattern and
affect all funiculi and involve mainly general propriocep-
tive sensory, somatic sensory and motor tracts, but lack
observable neuronal cell body degeneration or loss [5,6].
Diagnosis of CDM is not straightforward, since similar
clinical signs are seen with other neurological diseases,
such as intervertebral disc or lumbosacral disease. There
is no definitive ante-mortem diagnostic test for CDMand the diagnosis is usually based on exclusion of other
neurological diseases [3], although co-morbidities can be
present.
Similarities have been observed between CDM and the
motor neurone disease, amyotrophic lateral sclerosis (ALS)
in humans. ALS is a disease typically seen between the ages
of 45 and 60, where degeneration of the upper and lower
motor neurons culminates in paralysis and death [7]. Gen-
etic studies in familial ALS identified an association be-
tween the disease and mutations in the gene encoding
superoxide dismutase 1 (SOD1) [8]. SOD1 is an enzyme
involved in scavenging of superoxide free radicals within
cells and thus plays an important role in prevention of
oxidative damage. Studies suggest enzyme activity is
unaffected by the presence of SOD1 mutations; instead
proteins encoded by the mutated version of the gene
demonstrate an increased propensity to form aggre-
gates [9,10], although it has yet to be established how
this relates to the pathogenesis of neuronal dysfunction
seen in ALS and CDM. To date, over 160 different
point mutations in the SOD1 gene have been identified
in ALS patients [11], with approximately 20% of all fa-
milial cases and 1-2% of sporadic cases due to muta-
tions in this gene [7,12].
A previous study by Awano and colleagues [13] identified
a mutation in the canine SOD1 gene (SOD1:c.118G >A),
where a G to A substitution in exon 2 causes an E40K mis-
sense mutation. Homozygosity for the A allele was strongly
associated with CDM in the five breeds examined (Pem-
broke Welsh Corgi, Boxer, Rhodesian ridgeback, GSD and
Chesapeake Bay retriever), where 96% of dogs diagnosed
with CDM were A/A homozygous compared to 34% in the
control dogs. In their North American population of GSDs,
4 out of 5 affected dogs were homozygous for the mutant
A allele, compared to only 7 of 120 control GSDs, suggest-
ing that genotyping for this mutation in GSDs might pro-
vide important diagnostic information. Therefore, the aim
of the present study was to develop a simple genotyping
test for the SOD1:c.118G >A mutation and to estimate the
prevalence of this mutation in a UK population of GSDs.
Results
The aim of this study was to develop a simple genotyp-
ing test for the SOD1:c.118G > A mutation using PCR
followed by Restriction Fragment Length Polymorphism
(RFLP). The G to A change at position 118 caused by
the mutation alters a restriction digestion site, recog-
nised by the Eco571 enzyme (CTGAAG(N)16), such that
the DNA from the wild type (G) allele can be cut but
that from the mutant (A) allele cannot.
Genomic DNA from two GSDs of each SOD1 geno-
type, as determined by direct sequencing, was initially
used to evaluate the RFLP assay. The initial PCR reac-
tion produces a single amplicon of 292 bp which, after
Figure 2 Prevalence of SOD1:c.118G > A in a UK population of
GSDs. GSDs were grouped according to their age/clinical status and
SOD1 genotype. Statistical analysis was undertaken using the Fishers
Exact Test with a Bonferroni correction to compare the proportion
of dogs homozygous for the mutation in each of the groups
(*p < 0.05, ***p < 0.001).
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ing on the SOD1 genotype (Figure 1). In dogs with the
homozygous G/G genotype, bands at 230 bp and 62 bp
are present after digestion, whereas in the homozygous
A/A mutant genotype, no digestion occurs and the ori-
ginal band at 292 bp remains. In the heterozygous G/A
genotype, three bands are seen at 292 bp, 230 bp and
62 bp. Incomplete digestion of the PCR product in homo-
zygous G/G dogs sometimes resulted in a feint band being
visible at 292 bp after digestion, but this could be clearly
distinguished from the more intense band representing
the undigested fragment obtained after digestion in het-
erozygous G/A dogs.
One hundred and fifty GSDs, referred to a veterinary
tertiary hospital in the UK between 2005 and 2010, were
genotyped for the SOD1:c.118G > A mutation. The study
population consisted of 50 dogs aged less than 6 years
(i.e. before any clinical signs of CDM would be antici-
pated), 50 dogs over 8 years of age referred to the hos-
pital neurology service with pelvic limb ataxia as a
major clinical sign and 50 dogs over 8 years of age, re-
ferred to other clinical services with no neurological
disease reported.
The number of dogs displaying each of the SOD1 geno-
types was found to vary in the three populations of GSDs
examined (Figure 2). In the population of GSDs less than
6 years of age, 8 were homozygous mutant (A/A), 19 were
heterozygous (G/A) and 23 dogs were homozygous wild
type (G/G), which relates to an allele frequency of 0.35 for
the SOD1:c.118A mutation in this GSD population. In the
population of GSDs older than 8 years of age with non-
neurological conditions, no dogs were homozygous (A/A),
26 were heterozygous (G/A) and 24 were homozygous
(G/G), which gives an allele frequency 0.26 for the mu-
tation. The frequency of dogs homozygous for the AFigure 1 RFLP analysis of three GSD, previously genotyped for
SOD1:c.118G > A. M = DNA ladder with relevant sized bands
indicated, U = undigested PCR product, D = PCR product
digested with Eco571. The digested G/G genotype shows bands at
230 bp and 62 bp, no digestion has occurred with the A/A
genotype, and with the digested heterozygous A/G genotype, three
bands are visible at 292 bp, 230 bp and 62 bp.allele was significantly lower in the dogs with non-
neurological conditions compared to the young GSD
population (p = 0.017). In the neurology case population
of GSDs older than 8 years of age, 21 were homozygous
(A/A), 10 were heterozygous (G/A) and 19 dogs were
homozygous (G/G), which gives an allele frequency of
0.52 for the mutation. The frequency of dogs homozygous
for the A allele in the ataxic case population is signifi-
cantly higher than in both the young GSD population
(p = 0.023) and the non-neurological case population
(p < 0.001). However, when the results for GSDs over
8 years of age are combined (i.e. both ataxic and non-
neurological cases) and compared with the young GSDs,
there were no significant differences in allele or genotype
frequencies. The allele frequency for the SOD1:c.118A
mutation overall was 0.38.
Discussion
The SOD1:c.118G > A mutation, associated with CDM,
was originally identified in a genome-wide association
study and characterised by sequence-based typing [13].
Recent studies have used conventional and real-time
PCR techniques to develop more rapid and cost-effective
methods of genotyping dogs for this particular mutation
[14-16]. The present study employed PCR followed by
RFLP analysis, utilising the Eco571 enzyme, demonstrat-
ing that this technique allows rapid and simple genotyp-
ing dogs for the SOD1:c.118G > A mutation.
There was no significant difference in allele or geno-
type frequencies comparing young GSDs (n = 50) with
those over 8 years of age (n = 100) in the sample popula-
tion from a large tertiary veterinary hospital. In dogs
over 8 years of age, homozygosity for the SOD1:c.118A
allele was strongly associated with those affected with
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non-neurological disease. None of the 50 dogs with
non-neurological conditions were of the A/A genotype,
compared with 21 of 50 dogs with neurological signs
being homozygous for this mutation. This is a lower
proportion of homozygous A/A mutant dogs than that
identified in the American GSD CDM case population
examined by Awano and colleagues [13], where 4 of 5 dogs
were homozygous for the A allele, but similar to that found
in an Italian study, where 3 of 10 GSD in their case popula-
tion were homozygous A/A [15]. This might represent
genetic variability, due to geographical differences in the
gene pool of GSD populations studied, but more likely re-
sults from differences in selection criteria used for identify-
ing the case populations. In both the current and the
Italian study, selection of the case population was based on
a broad phenotype, relating to neurological signs (such
lower limb ataxia in this study), compared with the study
of dogs in the USA, where a more definite diagnosis of
CDM was made following post-mortem histopathology or
MRI studies. Thus, although CDM cases would be in-
cluded in our case population, this is a relatively heteroge-
neous group, with other causes of pelvic limb ataxia also
likely to be represented.
Use of SOD1 genotyping in a clinical setting is now
considered to be a useful component of the diagnostic
panel, with dogs showing consistent clinical signs and
being homozygous for the mutation, raising the index of
suspicion of CDM, whereas those with heterozygous or
homozygous wild-type genotypes considered more likely
to be affected by other disease processes. As manage-
ment of CDM is problematic, with the disease often rap-
idly progressing, the results of such a genetic test may
influence the treatment the dog receives, particularly in
those dog with co-morbidities, whereby it may not be
appropriate to consider surgical intervention for concur-
rent spinal conditions, in a dog that is homozygous for
the SOD1:c.118G > A mutation, but to opt instead for
physiotherapy which has been shown to prolong life in
dogs with CDM [17].
Although CDM appears to be inherited in an autosomal
recessive manner, with incomplete penetrance [13], in our
study of UK GSDs, all dogs over 8 years of age that
expressed the A/A genotype were showing clinical signs of
ataxia, with none of the ‘neurologically healthy’ dogs ex-
pressing this genotype. This suggests that, in the UK at
least, penetrance is relatively high if not complete.
We also assessed the prevalence of the SOD1:c.118G >A
mutation in a cross-sectional study of relatively young
GSDs, which would be unbiased with respect to CDM
susceptibility because they are too young to show clinical
signs. The prevalence of the SOD1:c.118A allele in this
population was estimated to be 0.35, with 8 of 50 dogs
(16%) being homozygous for the A allele. Other studies[13,15] using limited numbers of dogs have estimated the
prevalence of the SOD1:c.118A allele in GSDs to be 0.17-
0.21 with 4–6% being AA homozygous. However, these
GSD populations were from different geographical loca-
tions and included dogs aged 0 to 14 years with and with-
out evidence of neurological disease, and therefore do not
necessarily represent the GSD population as a whole. A
much larger study [16], where over 6000 GSDs were geno-
typed for the SOD1:c.118G > A mutation, revealed a fre-
quency of 0.37 for the SOD1:c.118A allele with 22% being
AA homozygotes, which is similar to the results from the
present study. Follow up on the eight A/A homozygous
dogs identified in the present study revealed that one dog
had been euthanased due to clinical signs consistent with
CDM, four dogs had been euthanased before reaching
7 years of age for other conditions such as neoplasia and
liver disease, and three dogs currently remain disease free
at 8 years of age, although they might still develop CDM
in the future.
It has been suggested that genetic screening of dogs
for the SOD1:c.118G > A mutation in breeds known to
be susceptible to CDM might be used to influence
breeding programs [3]. Genetic testing and identification
of heterozygous or homozygous mutant dogs, alongside
a strategy for ensuring that they are only bred to homo-
zygous wild-type dogs, would reduce the prevalence of
the SOD1 mutation in the population over several gen-
erations. A more radical approach, based on selection
against all carriers of the mutation for breeding pur-
poses, could pose a problem in terms of restricting gen-
etic diversity, particularly in a breed such as the GSD,
where the prevalence of the A allele is relatively high.
In breeds such as the Boxer and Pembroke Welsh
Corgi, where the prevalence of the A allele is even
higher (A allele frequency is estimated to be over 0.7
in some studies [13]), breeding programs to select
against dogs carrying the mutant A allele would likely
have a major impact on the overall genetic health of
these breeds, thus eliminating desirable qualities or
unintentionally selecting for other genetic mutations.
Conclusions
We have found the RFLP assay for the canine SOD1:
c.118G > A mutation to allow rapid and cost-effective
genotyping of GSD. Since no definitive ante-mortem test
is available for CDM, this simple genetic test provides
useful information to the clinician, faced with a dog
demonstrating clinical signs where CDM is a differential
diagnosis. This is particularly valuable for treatment
planning and prognostication, especially when neurological/
musculoskeletal co-morbidities exist. Careful consideration
should be given when recommending more wide ranging
genetic testing of younger GSD for selection of dogs for
breeding, since there is a relatively high allele frequency
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the population. A more measured approach to reducing
the prevalence of this particular mutation in the GSD
population by avoiding breeding of carriers/affected dogs
with those of a similar genotype would be recommended.
Methods
EDTA blood samples were obtained from the genetic arch-
ive of the Royal Veterinary College, University of London.
Samples were from GSD (n = 150) that had been referred
to the Queen Mother Hospital for Animals between 2005
and 2010 and had been archived following completion of
diagnostic testing and with informed owner consent for
their use in clinical research. The samples selected con-
sisted of 50 dogs <6 years of age, 50 dogs >8 years of age,
referred for neurological assessment and with pelvic limb
ataxia as a major clinical sign and 50 dogs >8 years of age
referred to other clinical services with no neurological dis-
ease reported.
Genomic DNA was extracted from EDTA blood using
the GenElute Blood Genomic Kit (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. The isolated
DNA was then used in PCR to amplify a region of the
canine SOD1 gene. Primers (Sigma-Aldrich) were de-
signed that flank the mutation region of the SOD-1 gene
to generate a 292 base pair (bp) amplicon. The primers
used were sense: 5′-AGTGGGCCTGTTGTGGTATC-3′
and antisense: 5′-TCTTCCCTTTCCTTTCCACA-3′. The
PCR was performed in 25 μl reaction volumes using
Immolase DNA polymerase (Bioline), with 2 μl genomic
DNA as template and 2 μl of 10 pmol/μl primers. Thermo-
cycling conditions consisted of an initial polymerase ac-
tivation at 95°C for 10 min, followed by 37 cycles of
94°C for 40 s (denaturation), 55°C for 30 s (annealing)
and 72°C for 1 min (elongation) with a final extention
step of 72°C for 10 min (G-Storm GS1 thermal cycler, GRI).
The PCR products were purified using the GenElute
PCR Clean-up Kit (Sigma-Aldrich) and then digested
using Eco571 (Fermentas) for 1 h at 37°C. Digested PCR
products were analysed by 2% agarose gel electrophor-
esis containing 6% Safe View Nucleic acid Stain (NBS
Biologicals Ltd.) and using a 100 bp molecular weight
ladder (Hyperladder IV, Bioline) to determine product
sizes. The gels were visualised under UV light (Image-
Master VDS, Pharmacia Biotech/GE Healthcare).
The proportion of homozygous mutants in each group
(n = 3) was compared using the Fisher’s exact test with a
Bonferroni correction for multiple comparisons.
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